Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5392-5401

  Tanaka, Makito ^a,b,c   Butler, Marcus O ^a,b,c   Ansén, Sascha ^a,b,c   Imataki, Osamu ^a,b,c   Berezovskaya, Alla ^a   Nadler, Lee M ^a,b,c   Hirano, Naoto ^a,b,c,d,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; GAMMA INTERFERON; GENE PRODUCT; HLA DP ANTIGEN; HUMAN LEUKOCYTE ANTIGEN DP4; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 4; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN LAG 3; SURVIVIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON PRODUCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL; TH2 CELL;

ALLELES; AMINO ACID SEQUENCE; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD80; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-DP BETA-CHAINS; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-4; K562 CELLS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHOSPHOPROTEINS; TH1 CELLS; TH2 CELLS; VIRAL MATRIX PROTEINS;

EID: 80051682560     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3083     Document Type: Article

References (50)

1. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
2. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007;28:1133-1139 (Pubitemid 47062670)
3. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008;26:5198-5203
4. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anticancer therapy. Cancer Treat Rev 2009;35:553-562
5. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61:5964-5968 (Pubitemid 32768582)
6. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002;8:1731-1739 (Pubitemid 34633728)
7. Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 2004;108:937-941 (Pubitemid 38112625)
8. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-576 (Pubitemid 36841977)
9. Siegel S, Wagner A, Schmitz N, Zeis M. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 2003;122:911-914 (Pubitemid 37174610)
10. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003;9:6523-6533 (Pubitemid 38031841)
11. Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19.
12. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006;55:1294-1298 (Pubitemid 43992055)
13. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009;32:498-507.
14. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-728 (Pubitemid 40977140)
15. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008;222:129-144 (Pubitemid 351430378)
16. Schultz ES, Lethe B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4 +cytolytic T lymphocytes. Cancer Res 2000;60:6272-6275
17. +) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A 2001;98:3964-3969
18. Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002;169:6928-6934 (Pubitemid 36899279)
19. de Graaff PM, Heidema J, Poelen MC, van Dijk ME, Lukens MV, van Gestel SP, et al. HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology 2004;326:220-230 (Pubitemid 39078254)
20. + T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule. J Immunol 2006;176:5401-5408
21. + T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol 2008;181:431-439
22. Hirano N, Butler MO, Xia Z, Ansen S, von Bergwelt-Baildon MS, Neuberg D, et al. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 2006;107:1528-1536 (Pubitemid 43242391)
23. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, Murray AP, et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 2007;13:1857-1867 (Pubitemid 46952956)
24. Ansen S, Butler MO, Berezovskaya A, Murray AP, Stevenson K, Nadler LM, et al. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res 2008;14:6125-6136
25. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansen S, et al. Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 2006;108:2662-2668
26. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansen S, et al. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 2006;12:2967-2975 (Pubitemid 43837340)
27. Hirano N, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996;10:1168-1176 (Pubitemid 26254022)
28. Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008;111:5326-5333
29. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005;175:2261-2269 (Pubitemid 41113833)
30. Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007;13:5991-5994 (Pubitemid 350075053)
31. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-5320 (Pubitemid 28551107)
32. Lanzavecchia A, Reid PA, Watts C. Irreversible association of peptides with class II MHC molecules in living cells. Nature 1992;357:249-252
33. Butler MO, Ansen S, Tanaka M, Imataki O, Berezovskaya A, Mooney MM, et al. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol 2010;22:863-873
34. Ahmed R, Bevan MJ, Reiner SL, Fearon DT. The precursors of memory: models and controversies. Nat Rev Immunol 2009;9:662-668
35. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, et al. Establishment of Antitumor Memory in Humans Using in Vitro-Educated CD8+ T Cells. Sci Transl Med 2011;3:80ra34.
36. James EA, LaFond R, Durinovic-Bello I, Kwok W. Visualizing antigen specific CD4 +T cells using MHC class II tetramers. J Vis Exp 2009.
37. Vollers SS, Stern LJ. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 2008;123:305-313 (Pubitemid 351171199)
38. Johnson LD, Jameson SC. Immunology. A chronic need for IL-21. Science 2009;324:1525-1526
39. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 2006;24:519-540
40. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 2008;111:229-235
41. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006;5:1087-1098 (Pubitemid 43881300)
42. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 2007;4:174-191 (Pubitemid 350171819)
43. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003;99:738-745 (Pubitemid 37168044)
44. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 2005;49:353-361 (Pubitemid 41139148)
45. Taubert H, Kappler M, Bache M, Bartel F, Kohler T, Lautenschlager C, et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 2005;24:5258-5261 (Pubitemid 41192443)
46. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, et al. Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 2007;33:67-76. (Pubitemid 46090311)
47. O'Driscoll L, Linehan R, S MK, Cronin D, Purcell R, Glynn S, et al. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201:225-236 (Pubitemid 37357172)
48. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006;281:1286-1295
49. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005;24:1994-2007. (Pubitemid 40520508)
50. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill AD, et al. Expression of survivin and its splice variants survivin-2B and survivin- DeltaEx3 in breast cancer. Br J Cancer 2005;92:120-124 (Pubitemid 40188444)